Affidea completed the acquisition of a majority stake in LabPoint from Lindenhofgruppe.

Affidea, a pan-European provider of diagnostic imaging, polyclinic, and specialist healthcare services, completed the acquisition of a majority stake in LabPoint, a Swiss medical laboratory company providing comprehensive diagnostic services, from Lindenhofgruppe, a privately operated Swiss hospital group. Financial terms were not disclosed. “The integration of LabPoint reinforces one of Affidea’s core beliefs: precise diagnosis, built on the convergence of imaging, pathology and genetics are the foundation of modern, personalised medicine. This complementarity opens new opportunities to refine our clinical pathways, and provide physicians with a stronger decision-making foundation, ultimately benefiting the millions of patients we serve across Europe,” Charles Niehaus, Affidea Group Executive Director.